George Pappas

Chief Executive Officer @Delphian Therapeutics

Chicago IL, US

Delphian is optimizing Endocannabinoid System targeting to treat large pain and central nervous system disorders, with a lead indication in migraine, one of the world\'s most debilitating, most poorly managed diseases, afflicting over 1 billion people worldwide.The ECS is a high-level regulator of multiple biological systems. Highly selective targeting of CB1 or CB2 holds limited promise to tap the system\'s full therapeutic potential. Instead, ECS modulation is optimized by targeting multiple sites at once, using compounds that have well-established safety profiles to remove any unpredictability of off-target effects.Delphian is funded in part by the Migraine Research Foundation and the U.S. National Institutes of Health.

University of Iowa

BA, Political Science, International Studies